Cardiff Oncology Reports Promising Results in mCRC Trial with Onvansertib
Cardiff Oncology, Inc. has announced encouraging results from its ongoing Phase 2 clinical trial, CRDF-004, which evaluates the efficacy of onvansertib in combination with standard-of-care treatments for patients with first-line…